Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial (vol 23, pg 117, 2023)

被引：0
|
作者：
Wedemeyer, H.
Schoneweis, K.
Bogomolov, P.
机构：
来源：
LANCET INFECTIOUS DISEASES | 2022年 / 22卷 / 12期
关键词：
D O I：
10.1016/S1473-3099(22)00657-0
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E348 / E348
页数：1
相关论文
共 39 条
  • [31] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
    Sulkowski, Mark
    Hezode, Christophe
    Gerstoft, Jan
    Vierling, John M.
    Mallolas, Josep
    Pol, Stanislas
    Kugelmas, Marcelo
    Murillo, Abel
    Weis, Nina
    Nahass, Ronald
    Shibolet, Oren
    Serfaty, Lawrence
    Bourliere, Marc
    Dejesus, Edwin
    Zuckerman, Eli
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973): : 1087 - 1097
  • [32] Safety, tolerability, and anti-fibrotic efficacy of the CBP/I3-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
    Kimura, Kiminori
    Kanto, Tatsuya
    Shimoda, Shinji
    Harada, Kenichi
    Kimura, Masamichi
    Nishikawa, Koji
    Imamura, Jun
    Ogawa, Eiichi
    Saio, Masanao
    Ikura, Yoshihiro
    Okusaka, Takuji
    Inoue, Kazuaki
    Ishikawa, Tetsuya
    Ieiri, Ichiro
    Kishimoto, Junji
    Todaka, Koji
    Kamisawa, Terumi
    EBIOMEDICINE, 2022, 80
  • [33] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
    Aroda, Vanita R.
    Bain, Stephen C.
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Axelsen, Mads
    Rowe, Everton
    DeVries, J. Hans
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05): : 355 - 366
  • [34] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (vol 385, 1087, 2015)
    Sulkowski, M.
    Hezode, C.
    Gerstoft, J.
    LANCET, 2015, 385 (9973): : 1074 - 1074
  • [35] Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial (vol 6, pg 448, 2021)
    Andrieux-Meyer, I
    Tan, S-S
    Thanprasertsuk, S.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 704 - 704
  • [36] INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
    Naidoo, Anushka
    Dooley, Kelly E.
    Naidoo, Kogieleum
    Padayatchi, Nesri
    Yende-Zuma, Nonhlanhla
    Perumal, Rubeshan
    Dorse, Gillian
    Boodhram, Resha
    Osuala, Emmanuella Chinonso
    BMJ OPEN, 2022, 12 (11):
  • [37] Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
    Lawitz, Eric
    Buti, Maria
    Vierling, John M.
    Almasio, Piero L.
    Bruno, Savino
    Ruane, Peter J.
    Hassanein, Tarek I.
    Muellhaupt, Beat
    Pearlman, Brian
    Jancoriene, Ligita
    Gao, Wei
    Huang, Hsueh-Cheng
    Shepherd, Aimee
    Tannenbaum, Brynne
    Fernsler, Doreen
    Li, Jerry J.
    Grandhi, Anjana
    Liu, Hong
    Su, Feng-Hsiu
    Wan, Shuyan
    Dutko, Frank J.
    Nguyen, Bach-Yen T.
    Wahl, Janice
    Robertson, Michael N.
    Barr, Eliav
    Yeh, Wendy W.
    Plank, Rebeca M.
    Butterton, Joan R.
    Yoshida, Eric M.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (11): : 814 - 823
  • [38] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
    Lawitz, Eric
    Gane, Edward
    Pearlman, Brian
    Tam, Edward
    Ghesquiere, Wayne
    Guyader, Dominique
    Alric, Laurent
    Bronowicki, Jean-Pierre
    Lester, Laura
    Sievert, William
    Ghalib, Reem
    Balart, Luis
    Sund, Fredrik
    Lagging, Martin
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973): : 1075 - 1086
  • [39] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial (vol 10, pg 407, 2022)
    Battelino, T.
    Bergenstal, R. M.
    Rodriguez, A.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (08): : E8 - E8
1234